As shown by our data, administration of DHZCPs significantly increased the expression levels of ghrelin and adiponectin but decreased the expression level of leptin in NAFLD patients treated with DHZCPs. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.